ClinicalTrials.gg
RecruitingNCT07458906Updated Sep 25, 2026

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

An interventional study of Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT in DLL3-expressing Tumors, PET / CT and Neuroendocrine Cancer, sponsored by The First Affiliated Hospital of Xiamen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by The First Affiliated Hospital of Xiamen University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Sep 25, 2026Start date movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Carcinoma, Neuroendocrine with a site in China — 26 open to participants now, 27 under way, 4 of them phase 3. Carcinoma, Neuroendocrine · China.

Planned enrollment
16th of 32
80 · median 80
Started
2026
with 10 others
No phase
Only one
of the 39
Primary completion
2026-12
later than 7 of 26 live
Registered
29th of 39
by date

Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, this one is the 16th largest by planned enrollment of the 32 interventional ones that give a count, is one of 11 that started in 2026, is the only one with no phase, reaches primary completion later than 7 of the 26 other live ones, and was the 29th registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 65 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

26 of the 39 studies in Carcinoma, Neuroendocrine with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Carcinoma, Neuroendocrine studies recruiting now, 29 (63%) set no upper age limit and 10 (22%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Carcinoma, Neuroendocrine with a site in China, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.

Read the detailed description

This study is designed to investigate DLL3-targeted PET/CT as a noninvasive approach for detecting tumor lesions in patients with suspected or confirmed neuroendocrine carcinoma.

In this research, patients with neuroendocrine carcinoma or highly suspected recurrence detection underwent contemporaneous DLL3-targeted PET/CT and conventional imaging (such as CT, MRI or 18F-FDG) either for an initial assessment or for metastases or highly suspected recurrence detection. Tumor uptake was quantified by the maximum standardized uptake value (SUVmax). By correlating immunohistochemistry with tumor uptake of the DLL3-targeted tracer, the investigators will explore the feasibility of visualizing tumor DLL3 expression using DLL3-targeted PET. The numbers of positive tumor lesions of conventional imaging and DLL3-targeted PET/CT were recorded by visual interpretation. The diagnostic accuracy of DLL3-targeted was calculated and compared to conventional imaging. Intertumoral heterogeneity was assessed using the coefficient of variation (CV) of SUVmax across all lesions within each patient.

03

Conditions studied

  • DLL3-expressing Tumors
  • PET / CT
  • Neuroendocrine Cancer

Keywords

  • DLL3-expressing tumors
  • PET/CT
  • Neuroendocrine Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (aged 18 years or older);
  • Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report);
  • Serum ProGRP or NSE level ≥ 3 times the ;
  • Patients who were able to provide (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
  • Estimated of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;

Exclusion criteria

Exclusion Criteria:

  • The inability or unwillingness of the research participant or legal representative to provide written .
  • Inability to complete PET/CT imaging.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    DLL3-targeted PET/CT

    Each subject receives a single intravenous injection of DLL3-targeted probe and undergoes PET/CT imaging within the specified time.

    Diagnostic Test: Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT

Interventions

  • Diagnostic testDiagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT

    Participants will undergo DLL3-Targeted PET/CT imaging for the evaluation of tumor lesions. Imaging findings will be compared with conventional imaging modalities as part of the study analysis.

06

What researchers measure

Primary outcomes

  1. Changes in vital signs after administration of the DLL3-targeted tracer

    Vital signs will be monitored before and after administration of the DLL3-targeted tracer, including body temperature, pulse rate, respiratory rate, and blood pressure. Units of Measure: Body temperature (°C); Pulse rate (beats/min); Respiratory rate (breaths/min); Blood pressure (mmHg).

    Time frame: 1 day

  2. Radiation absorbed dose of the DLL3-targeted PET tracer in normal organs and whole body

    Radiation dosimetry will be calculated using serial whole-body PET/CT imaging after administration of the DLL3-targeted tracer. Time-activity curves will be generated for major organs, and absorbed doses will be estimated using standard internal dosimetry software (e.g., OLINDA/EXM). Unit of Measure: Absorbed radiation dose (mGy/MBq).

    Time frame: 1 year

Secondary outcomes

  1. Correlation between tumor DLL3 expression assessed by immunohistochemistry (H-score) and tumor uptake of the DLL3-targeted PET tracer (SUVmax)

    Tumor DLL3 expression will be quantified using immunohistochemistry (IHC) and reported as an H-score (range 0-300). Tumor uptake of the DLL3-targeted PET tracer will be measured as maximum standardized uptake value (SUVmax) on PET/CT imaging. The correlation between DLL3 IHC H-score and PET SUVmax will be analyzed to evaluate the feasibility of noninvasively visualizing and quantifying tumor DLL3 expression using DLL3-targeted PET imaging.

    Time frame: 1 year

Other outcomes

  1. Intertumoral heterogeneity

    Intertumoral heterogeneity of DLL3 was assessed using the coefficient of variation (CV) of SUVmax across all lesions within each patient.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Mar 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2026
First posted
Mar 9, 2026
StartActual
Mar 10, 2026was Dec 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 1, 2025→Mar 10, 2026
Sep 25, 2026
Enrollment
60→80
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Start date Dec 1, 2025→Mar 10, 2026
    Enrollment 60→80

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07458906
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Mar 10, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 25, 2026

Study contacts

Liang Zhao
Contact
wzhaoliang01@163.com
86 18818350620
Haojun Chen
Contact
leochen0821@foxmail.com
86 18659285282

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion